Jubilant Draximage Radiopharmacies, Inc.

Jubilant Draximage Radiopharmacies, Inc., doing business as Jubilant Radiopharma, manufactures and supplies radiopharmaceuticals and nuclear medicine products to the Department of Veterans Affairs and Defense Health Agency as a prime contractor, holding a self-certified small disadvantaged business designation and a subsidiary position under Jubilant Life Sciences Limited. The vendor operates from facilities in Orlando, Orlovista, and Norcross, Florida; Boston and West Roxbury, Massachusetts; and other locations, competing exclusively in full-and-open procurement without set-aside restrictions across all recent awards.

Jubilant Radiopharma's capability portfolio centers on radiopharmaceutical manufacturing and distribution — specifically diagnostic imaging agents and therapeutic medical isotopes including Gallium 68 Dotatate, iodine I-123, and technetium-99m used in positron emission tomography scans, cardiac imaging, and oncology diagnostics. Representative work includes a $231,772.50 firm fixed-price delivery order from VA Veterans Integrated Service Network 8 (VISN 8) for Gallium 68 Dotatate with performance through March 2027; a $771,410.67 blanket purchase agreement call from VISN 1 for radiopharmaceuticals through January 2027; and a $713,865 purchase order from VISN 7 for Cu-64 dotatate with ultimate completion in February 2027. The vendor also holds a $1.5 million single-award indefinite delivery contract with VISN 8 for Gallium 68 Dotatate (March 2022–March 2027) and a $740,177.94 single-award indefinite delivery contract with VISN 12 for radiopharmaceuticals (February 2025–January 2028), with multiple delivery orders issued under both vehicles.

Customer concentration is overwhelming and singular. The Department of Veterans Affairs Veterans Health Administration accounts for all 78 prime awards in the source footprint across thirteen distinct regional service networks. By potential value, VISN 6 dominates with $178.8 million combined value across 7 awards (83% of the vendor's total $214 million combined potential value), a material concentration cliff driven by a single large indefinite delivery contract (IDC 36C24619D0019, $177.1 million ceiling). By award count, VISN 12 leads with 18 awards valued at $6.3 million combined, followed by VISN 21 (12 awards, $2.1 million) and VISN 1 (9 awards, $10.3 million). This concentration divergence — VISN 6 anchoring most dollars through one large IDC while VISN 12 places the most discrete orders — reflects both baseline supply agreements and ongoing task order execution across the VA's regional networks.

The vendor's parent-vehicle position is anchored by a small set of large IDCs. Indefinite Delivery Contract 36C24619D0019 (VISN 6) carries the $177.1 million ceiling with 6 task orders. IDC VA26017D0044 (VISN 1) holds 6 task orders for $1.6 million combined value. IDC 36C24822D0048 (VISN 12) carries 5 task orders worth $2.2 million combined value. A Defense Health Agency single-award blanket purchase agreement (BPA 36C24121A0025) with Naval Hospital Pensacola holds $150,000 ceiling and has generated 6 calls. The vendor does not hold positions on government-wide acquisition contracts, GSA Schedules, or multi-agency IDIQs; all awards are single-award or BPA vehicles at individual VA regional networks or the Defense Health Agency.

Activity has contracted since the 2022 peak of 12 awards. The vendor received 12 awards in 2022, declined to 6 in 2023 and 4 in 2024, recovered slightly to 5 in 2025, and shows 3 awards in 2026 (through March). Five awards carrying combined potential value of $2 million reach ultimate completion within the next twenty-four months, representing modest recompete exposure relative to the vendor's $214 million ceiling portfolio. The heavily weighted VISN 6 IDC (36C24619D0019) does not appear in the recompete-cliff block, indicating its ultimate completion date extends beyond twenty-four months from the source date, insulating the vendor's largest dollar position from near-term recompete risk.

The vendor operates as a pure prime contractor (78 awards, 100% prime split) with no recorded federal subcontract activity in the source footprint. Jubilant Radiopharma's competitive posture is non-set-aside across all awards; no single-source or sole-source 8(a) or other set-aside designations appear in the award chain. Primary NAICS concentrations are Pharmaceutical Preparation Manufacturing (62 awards) and In-Vitro Diagnostic Substance Manufacturing (11 awards), with corresponding PSC coding concentrated in Drugs and Biologicals (54 awards) and In Vitro Diagnostic Substances (13 awards), reflecting the vendor's narrow expertise in specialized radiopharmaceutical products rather than breadth across pharmaceutical or diagnostic categories.